---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-005035"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:33:14.010281+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Corvus Pharmaceuticals suspends $100M ATM equity offering program

## Summary
- Suspended $100M at-the-market offering; zero shares sold prior to suspension.
- Company notified Jefferies; no sales until new prospectus supplement or registration statement filed.
- Sale Agreement remains in full force and effect despite suspension.
- Company cites proposed registered underwritten public offering as context.

## SEC filing metadata
- accession: 0001104659-26-005035
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000110465926005035/0001104659-26-005035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000110465926005035/tm263501d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-005035
- JSON: https://secwatch.observer/filing/0001104659-26-005035.json
- Plain text: https://secwatch.observer/filing/0001104659-26-005035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.